Look, it's cute, but don't start with this garbage, please.
GSK is invested in Dynavax for 4 programs already. GSK doesn't have to do ANYTHING about Heplisav, the FDA just handed them the golden key by denying Heplisav. Nothing is quick in the world of biotech. There isn't any such thing as a "quick re-file". It's like dog-years; 1 biotech year is like 7 regular calendar years.....
All the call options with open interest, in and out of the money, totalled together would barely equal 5% of the company's outstanding. You're in denial, Joey. Just accept the facts like the rest of us longs -- it was rejected -- and load up, if you're in it for the long haul.
Yep, in it for the long haul...but sometimes I can't help but think I fit the definition of insanity: doing the same thing over again and expecting different results. Every time a binary event has come up for DVAX, the buttered side of the bread has landed on the floor.